Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE-EXTEND: Upadacitinib Extension in RA
NCT02049138Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Jan 2014; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02049138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049138.